Celldex Therapeutics, Inc. Forecast, price target & analysts
Celldex Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Celldex Therapeutics, Inc. Classifications & Recommendation:
Celldex Therapeutics, Inc. Price Target
| Target Price | $61.25 |
| Price | $20.93 |
| Potential |
192.64%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Celldex Therapeutics, Inc. 2026 .
The average Celldex Therapeutics, Inc. target price is $61.25.
This is
192.64%
register free of charge
$90.00
330.00%
register free of charge
$36.00
72.00%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend Celldex Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Celldex Therapeutics, Inc. stock has an average upside potential 2026 of
192.64%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.02 | 3.92 |
| 2.03% | 44.09% | |
| EBITDA Margin | -2,733.62% | -5,998.74% |
| 35.28% | 119.44% | |
| Net Margin | -2,316.33% | -5,541.34% |
| 17.77% | 139.23% |
13 Analysts have issued a sales forecast Celldex Therapeutics, Inc. 2025 . The average Celldex Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Celldex Therapeutics, Inc. EBITDA forecast 2025. The average Celldex Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Celldex Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Celldex Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.45 | -3.28 |
| 16.10% | 33.88% | |
| P/E | negative | |
| EV/Sales | 171.75 |
13 Analysts have issued a Celldex Therapeutics, Inc. forecast for earnings per share. The average Celldex Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Celldex Therapeutics, Inc....
Current Celldex Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jan 29 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
